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Abstract 
Vascular immune-inflammatory responses play a crucial role in the progression and outcome of 
atherosclerosis. The ability to assess localized inflammation through detection of specific vascular 
inflammatory biomarkers would significantly improve cardiovascular risk assessment and 
management; however, no multi-parameter molecular imaging technologies have been established 
to date. Here, we report the targeted in vivo imaging of multiple vascular biomarkers using 
antibody-functionalized nanoparticles and surface-enhanced Raman scattering (SERS). 
Methods: A series of antibody-functionalized gold nanoprobes (BFNP) were designed containing 
unique Raman signals in order to detect intercellular adhesion molecule 1 (ICAM-1), vascular cell 
adhesion molecule 1 (VCAM-1) and P-selectin using SERS. 
Results: SERS and BFNP were utilized to detect, discriminate and quantify ICAM-1, VCAM-1 and 
P-selectin in vitro on human endothelial cells and ex vivo in human coronary arteries. Ultimately, 
non-invasive multiplex imaging of adhesion molecules in a humanized mouse model was 
demonstrated in vivo following intravenous injection of the nanoprobes. 
Conclusion: This study demonstrates that multiplexed SERS-based molecular imaging can indicate 
the status of vascular inflammation in vivo and gives promise for SERS as a clinical imaging technique 
for cardiovascular disease in the future. 
Key words: atherosclerosis, molecular imaging, multiplexing, vascular inflammation, surface-enhanced Raman 
spectroscopy (SERS) 
Introduction 
Atherosclerosis arises from a combination of 
interacting genetic and lifestyle factors, leading to 
metabolic dysfunction and chronic inflammation [1,2]. 
It underlies the majority of adverse cardiovascular 
disease (CVD) outcomes that are the leading cause of 
death worldwide [3]. Diagnostic imaging technologies 
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such as magnetic resonance imaging (MRI), computed 
tomography (CT), ultrasound (US) and positron 
emission tomography (PET) have facilitated the 
anatomic imaging of atherosclerosis; however, these 
approaches lack the ability to predictively 
discriminate stable and vulnerable atherosclerotic 
disease [4-8]. Whilst inflammation plays a significant 
role in atherosclerosis onset and development, as well 
as plaque vulnerability, this understanding has not 
yet been successfully translated to allow for disease 
stratification or the reporting of successful 
intervention [9-11]. In this respect, the inability to 
image vascular inflammation in patients at the 
molecular level and identify those with prominent 
inflammatory disease components has been identified 
as a key clinical limitation, as this may facilitate 
cardiovascular risk assessment and management 
[11,12-14]. 
Surface-enhanced Raman spectroscopy (SERS) is 
a novel imaging modality with the potential to 
directly address these unmet clinical needs. SERS 
relies on noble metal nanoparticles (NPs) to enhance 
unique, fingerprint-like Raman signals from reporter 
molecules at or near the NP surface [15]. The spectral 
diversity of these reporter molecules and amenable 
NP surface chemistry make SERS highly attractive for 
multi-parameter molecular imaging [16,17]. 
SERS-active NPs have been successfully engineered to 
bind to biological molecules, with biofunctional 
nanoprobes (BFNP) composed of a NP core, reporter 
molecule, encapsulation layer and targeting 
biomolecule, facilitating the detection and 
discrimination of targeted biomarkers [16-19]. We 
previously demonstrated SERS-BFNP imaging of 
intercellular adhesion molecule (ICAM)-1 in the 
microvasculature of a murine ear [20]; however, 
whilst it has been shown that multiple BFNPs can be 
detected in tissues following local or non-targeted 
administration, targeted multiplex SERS imaging 
following intravenous injection has yet to be 
demonstrated [21,22]. In addition to ICAM-1, other 
adhesion molecules such as vascular cell adhesion 
molecule (VCAM)-1 and P-selectin, contribute to the 
recruitment of immune cells to atherosclerotic vessels 
and have been identified as attractive targets for the 
molecular imaging of vascular inflammation [12,23]. 
A multiplexed approach, reporting all of these 
markers via SERS-BFNP, could therefore represent a 
powerful, completely novel semi-quantitative 
imaging tool, but has yet to be explored in the context 
of atherosclerosis. Herein, we describe a 
SERS-BFNP-based strategy that offers the first 
multiplex targeted in vivo imaging of vascular 
inflammatory biomarkers with scalable potential to 
contribute across diseases and target tissues. 
Methods 
Mice 
NOD SCID Gamma mice (NSG) (originally 
purchased from Jackson Laboratories, Bar Harbor, 
ME, USA) were bred in-house (Central Research 
Facility, University of Glasgow, UK) and used for this 
study. NSG mice were bred in a sterile film isolator 
and maintained in individually ventilated cages 
(IVC). Animals were maintained on a 12/12-h 
light/dark cycle with free access to food and water, 
and all the procedures were performed in accordance 
with local ethical and UK Home Office regulations. 
Animals were randomly assigned to experimental 
groups and analyzed in a blinded fashion. 
Human adipose engraftment mouse model 
(HANSG) 
Subcutaneous adipose tissue from patients 
undergoing routine surgery was collected via the 
Greater Glasgow and Clyde NHS Biorepository. 
Experiments were approved by the West of Scotland 
Research Ethics Committee (application number 107, 
study title: In situ nanoparticle assemblies for 
atherosclerosis diagnosis and therapy). Adipose was 
dissected from surrounding tissue and cut into 
segments weighing approximately 0.5 g. Segments 
were then embedded in MatrigelTM (Corning, 
Tewksbury, MA) and cultured in endothelial cell 
culture media MV (Promocell, Heidelberg, Germany) 
for 7 days to promote the outgrowth of human blood 
vessels. NSG mice were anaesthetized using 
isoflurane in the prone position in a laminar flow 
hood and given Vetergesic (0.1 mg/kg) for pain relief. 
Mice were shaved using an electric shaver, and the 
surgery area cleaned using 70% 
ethanol/chlorhexidine. An incision was made in the 
back close to the shoulder blades, forceps were 
inserted and a pouch was created in the subcutaneous 
space. Matrigel embedded adipose tissue was then 
inserted into this pouch, and the incision sealed using 
surgical clips. Mice were allowed recovered on a heat 
mat within the laminar flow hood and subsequently 
housed in sterile IVCs. Surgical clips were removed 7 
days post-surgery. Engraftment was complete after 21 
days. All experiments were carried out between days 
21 and 28 days post-surgery. 
Cell culture 
Coronary artery endothelial cells (CAEC) 
(Promocell, Heidelberg, Germany; lot numbers 
4071602 and 397Z003) and human umbilical vein 
endothelial cells (HUVECs) (Thermo Fisher Scientific, 
Inchinnan, UK; lot number 1578351) were maintained 
in endothelial cell growth media MV (Promocell, 
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Heidelberg, Germany) supplemented with 
penicillin/streptomycin at 37 °C/5% CO2. 3×104 
CAEC/HUVEC were seeded into 8-well slide 
chambers and rested for 24 h. Cells were then 
stimulated with 10 ng/mL recombinant Human 
TNF-α (Peprotech, London, UK) for 24 h. 
Human heart tissue 
Human heart tissue collection was performed in 
collaboration with the Greater Glasgow and Clyde 
(GG&C) Bio-repository and was approved by the 
West of Scotland Research Ethics Committee 
(reference number: 10/S0704/60 and 16/WS/0207; 
application number 107, study title: In situ 
nanoparticle assemblies for atherosclerosis diagnosis 
and therapy). Explant human hearts were obtained 
under informed consent from patients undergoing 
heart transplantation at the Golden Jubilee National 
Hospital (GJNH) in Glasgow. Following removal, 
hearts were immediately placed in cold cardioplegic 
solution (lactated ringers, 2% St Thomas solution, 5 
mEq NaHCO3 and 10 mEq KCl; Thermo Fisher 
Scientific) and 2-3 cm segments of coronary arteries 
(LAD, RCA or circumflex) were dissected free from 
the surrounding myocardium before being 
transferred to the laboratory in cardioplegic solution 
on ice. 
Processing of coronary arteries for histology, 
immunofluorescent microscopy and SERS 
microscopy 
Segments of human coronary artery were 
cryo-embedded in OCT compound (Tissue Tek, 
Sakura Finetek Europe, Zoeterwoude, the 
Netherlands). 10 µm thick cryo-sections of tissue were 
fixed in 10% neutral buffered formalin and subject to 
hematoxylin and eosin (H&E) staining; lipid 
distribution in coronary arteries was observed using 
Oil Red O (ORO) staining. Stained sections were 
imaged using with an EVOS FL auto microscope 
(Thermo Fisher Scientific). 
Immunofluorescence microscopy (IFM) 
Samples (cells or tissues) were washed twice 
with PBS and fixed in ice-cold acetone for 5 min at 
room temperature, air dried, rehydrated in PBS and 
then blocked for 1 h in Dako Serum-Free Protein Block 
(DSFPB) (Agilent Technologies, Santa Clara, CA). 
Samples were incubated with purified primary 
antibodies (or suitable isotype matched controls) in 
DSFPB for 2 h at room temperature, washed in PBS, 
and then probed with Alexa-Fluor 647 labeled 
anti-Murine IgG raised in goat (Thermo Fisher 
Scientific) for 30 min. Following washing in PBS, 
samples were stained with fluorophore-conjugated 
primary antibodies for 2 h at room temperature if 
required. Samples were washed in PBS, 
counterstained with DAPI for 10 min and mounted 
with a coverslip using Vectashield mounting medium 
(Vector Laboratories, Burlingame, CA). 
Immunofluorescence images were acquired using a 
Zeiss Cell Observer SD confocal fluorescence 
microscope (Zeiss, Oberkochen, Germany). 
Fluorochrome-labeled antibodies: AF594 anti-CD31 
(catalogue number 303126; BioLegend, San Diego, 
CA), AF647 anti-mouse IgG raised in goat (catalogue 
number A21235; Thermo Fisher Scientific). 
Unconjugated antibodies for IFM: anti-ICAM-1, 
anti-VCAM-1, anti-P-selectin and IgG1 isotype control 
(catalogue numbers BBA3, BBA5, BBA30, MAB002 
respectively; R&D, Abingdon, UK). 
Transmission electron microscopy (TEM) 
CAEC were fixed in 2.5% glutaraldehyde, 4% 
paraformaldehyde, 0.1 M phosphate buffer, pH 7.2 
then washed in 0.1 M phosphate buffer, pH 7.2 and 
post-fixed in 1% OsO4 for 1 h on ice. After several 
washes in the same buffer, the samples were en bloc 
stained with 0.5% uranyl acetate in water for 30 min. 
Afterwards, samples were washed with water, 
dehydrated in ascending acetone series and resin 
embedded. Ultrathin sections were collected and 
imaged on a Jeol 1200 Transmission electron 
microscope (JEOL, Tokyo, Japan). All images obtained 
were analyzed and processed with FIJI software [24]. 
Flow cytometry 
Cell viability following exposure to BFNP and 
comparisons of fresh and implanted adipose tissue 
were performed using flow cytometry. Cell viability: 
Confluent HUVEC cultured in 6-well plates were 
exposed to increasing concentrations of isotype, 
anti-ICAM-1, anti-VCAM-1, and anti-P-selectin BFNP 
at a 1:1:1:1 ratio for 24 h. HUVEC were then isolated 
and suspended in 100 μL PBS containing e780 
viability dye (1:1000) (eBioscience, Waltham, MA, 
USA) and incubated for 10 min at 4 °C. HUVEC were 
then washed in PBS. Assessment of adipose tissue: 
The presence of human endothelial cells was 
determined using flow cytometry. Engrafted mice 
were culled 21 days post-surgery and their human 
adipose implants were removed. The tissues were 
minced and digested in 2% RPMI containing 1 
mg/mL collagenase II (Sigma Aldrich, Dorset, UK) 
and 10 U/mL DNase (Invitrogen, Carslbad, CA, USA) 
for 50 min at 37 °C under constant agitation. They 
were then mashed through a 100 µm filter and 
washed twice in 2% RPMI and once in PBS at 400 ×g 
for 5 min. The cell solutions were then suspended in 
400 µL PBS containing e520 viability dye (1:1000) 
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(eBiosciences, Waltham, MA, USA) and incubated for 
20 min at 4 °C. The cells were washed in PBS and 
resuspended in conditioned media from the 
anti-CD16/CD32 antibody producing hybridoma 
(2.4G2) (FcBlock). Antibody suspensions containing 
human Fc Block, V450-labelled anti-human CD36 
(both from BD Biosciences, San Jose, USA), 
APC-e780-labeled anti-human CD45, APC-labeled 
anti-mouse CD31, PE-labeled anti-human CD31, 
AF700-labeled anti-human CD34 (all from Biolegend, 
San Diego, CA, USA), PE-Cy7-labeled anti-mouse 
CD45 and PerCP-e710-labeled anti-human ICAM-1 
(both from eBiosciences, Waltham, MA, USA) were 
added to each sample and incubated for 20 min at 4 
°C. The cells were subsequently washed and analyzed 
using a BD LSRfortessa flow cytometer (BD 
Biosciences, San Jose, USA). Analysis of flow 
cytometry data was performed using FlowJo 10 
(FlowJo LLC, Ashland, OR, USA). 
Multiphoton imaging of adipose implants 
Multiphoton imaging was performed with a 
Zeiss LSM7 MP system equipped with 10×/0.3 NA air 
and a 20×/1.0 NA water immersion objective lenses 
(Zeiss, Cambridge, UK), a tunable titanium/sapphire 
solid-state 2-photon excitation source (Chamelon 
Ultra II; Coherent Inc., Glasgow, UK) and an optical 
parametric oscillator (OPO; Coherent Inc.). For 
multiphoton imaging, engrafted mice were given an 
intravenous injection of 20 µg of PE-labeled 
anti-human CD31. Following 1 h of incubation, the 
mice were culled and the implants were removed. 
Excised adipose tissue was bound with 
veterinary-grade glue (Vetbond; 3M, MN, US) to a 
plastic petri dish filled with warmed Ringer’s 
solution. A laser output of 820 nm and OPO signal at 
1060 nm provided excitation of adipocytes and 
hCD31-positive cells. Images were acquired with an 
X-Y pixel resolution of 512 × 512 in 3 μm Z 
increments. Images were processed using Volocity 
6.1.1 (Perkin Elmer, Cambridge, UK). 
Synthesis of biofunctional gold nanoprobes 
(BFNP) 
Citrate-reduced gold colloid nanoparticles 
(AuNP) were prepared using a modified Turkevich, 
Stevenson and Hillier method [25]. Briefly, 60.5 mg of 
sodium tetrachloroaurate dihydrate (Sigma-Aldrich, 
Dorset, UK) was added to 500 mL dH2O and heated 
until boiling. Upon boiling, an aqueous solution of 
sodium citrate tribasic dihydrate (Sigma-Aldrich) 
(57.5 mg in 7.5 mL) was added and boiling was 
maintained for 15 min. The solution was then allowed 
to cool to room temperature with continuous stirring 
maintained throughout. AuNP were functionalized 
with Raman reporters BPE (Sigma-Aldrich), PPY 
(Fluorochem, Hadfield, UK), PYOT (Sigma-Aldrich), 
DP (Sigma-Aldrich) as follows; 990 µL AuNP (52 pM) 
was mixed with 10 µL of Raman reporter (10 µM) for 
30 min at room temperature. The solution was then 
centrifuged at 2320 ×g for 20 min, the supernatant was 
removed and the pellet resuspended in 1 mL dH2O. 
Antibodies were directly conjugated to polyethylene 
glycol (PEG) (Thermo Fisher Scientific) as follows: 40 
µL of 1 mM polyethylene glycol (PEG; MW 5000) was 
premixed with 74 µL of 1 mg/mL 
N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide 
(Sigma-Aldrich). Twenty µL of the desired antibody 
(0.5 mg/mL anti-ICAM-1, anti-VCAM-1, anti-P- 
selectin or murine IgG1 isotype control; catalogue 
numbers BBA3, BBA5, BBA30, MAB002 respectively; 
R&D, Abingdon, UK) was premixed with 217 µL of 1 
mg/mL N-hydroxysulfosuccinimide sodium salt 
(Sigma-Aldrich). The two premixed solutions were 
combined, 709 µL of 10 mM HEPES (pH 7) buffer 
(Sigma-Aldrich) was added, and then the solution 
was gently agitated overnight. BFNP were completed 
by combining Raman reporter-functionalized AuNP 
with the antibody/PEG solution for 2-3 h. BFNP were 
then centrifuged at 2320 ×g for 20 min, the 
supernatant was removed, and the pellet was 
resuspended in 100 µL bovine serum 
albumin/sodium azide solution (0.1% / 2 mM; 
Sigma-Aldrich). Assembled conjugates typically had 
diameters around 80 nm, UV-VIS lambda max near 
530 nm (data not shown), and zeta potentials below 
-25 mW. Further details on the spectra and chemical 
structure of the Raman reporters used in this study 
can be found in [26]. 
Biofunctional nanoprobe (BFNP) 
characterisation 
BFNP were characterized for size, stability and 
SERS signal using UV-Visible spectroscopy, dynamic 
light scattering (DLS) and surface-enhanced Raman 
spectroscopy (SERS). UV-vis spectroscopy was 
carried out on a Varian Cary 3000 BioUV-Visible 
spectrophotometer (Agilent Technologies, CA, USA) 
with Win UV scan application version 2.00 software. 
The scanning wavelength range was 300-800 nm. All 
measurements (1 mL) were performed in disposable 
PMMA microcuvettes. Size and zeta measurements 
for each sample were recorded using a Malvern 
Zetasizer Nano ZS (Malvern, Worcestershire, UK) 
along with Zetasizer µV and APS version 6.20 
software. All samples (1 mL) were run in disposable 
PMMA macrocuvettes with a standard Malvern Dip 
Cell used for zeta measurements. SERS analysis of 
each sample was performed using the Snowy Range 
Sierra Series (Snowy Range Instruments, WY, USA) 
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with an excitation wavelength of 638 nm. Samples 
were analyzed using clear glass vials (Sigma Aldrich, 
Dorset, UK). Instrument settings for each sample were 
40 mW laser power with a 3 s acquisition time. 
In vitro immuno-SERS staining for SERS 
microscopy 
CAEC/HUVEC were cultured in 8-well EZ 
chamber slides (Merck Millipore, Burlington, MS) in 
unstimulated or TNF-α-stimulated conditions. Fixed 
cells: Cells were briefly fixed in ice-cold acetone then 
exposed to BFNP in bovine serum albumin/sodium 
azide /NaN3 solution at room temperature for 2 h. 
Cells were then washed thoroughly with PBS, rinsed 
in distilled water, and allowed to air dry for imaging. 
Live cells: CAEC were exposed to BFNP in endothelial 
cell growth media MV (Promocell, Heidelberg, 
Germany) at 37 °C/5% CO2 for up to 24 h. Cells were 
then washed thoroughly with PBS and fixed in 4% 
paraformaldehyde for 10 min. Slides were rinsed in 
distilled water and allowed to air dry prior to 
imaging. 
BFNP targeting of human coronary artery 
segments 
Coronary arteries were sealed with ligatures at 
each end prior to injection with BFNP resuspended in 
endothelial cell growth media MV (Promocell). 
Vessels were then incubated with BFNP for 12 h at 37 
°C/5% CO2. Sutures were then removed and 
unbound BFNP were removed with multiple PBS 
washes. Vessels were then subjected to 785 nm SERS 
spectroscopy, subsequently cryo-embedded in OCT 
compound and cut into 10 µm sections using a 
cryostat (Thermo Fisher Scientific) to facilitate 
analysis by SERS microscopy or IFM. 
BFNP targeting in vivo 
HANSG mice were injected with BFNP 
intravenously. SERS spectroscopy was then used to 
investigate grafts, liver, or small blood samples for 
SERS signal. Alternatively, or in addition, grafts were 
excised, cryo-embedded in OCT compound, cut into 
10 µm sections using a cryostat, and subjected to 
SERS/IFM microscopy. 
SERS microscopy 
Raman and darkfield images were acquired on a 
Renishaw InVia Raman microscope running WiRE 4.3 
software (Renishaw, Wotton-under-Edge, UK). The 
system was configured to utilize an upright 
microscope, piezo stage, 633 nm (HeNe) excitation, 
50×/0.75 NA Leica darkfield objective (Leica 
Microsystems, Cambridge, UK), 1800 l/mm grating 
and either the native Renishaw CCD camera or Andor 
EMCCD. Experimental parameters, including 
collection time (0.2 s Renishaw, 0.075 s EMCCD) and 
laser power (0.5 mW at sample) were optimized to 
ensure optimal SERS signal was observed from BFNP. 
The size of individual Raman maps varied from scan 
to scan; however, the same step size (1 µm) was used 
in both the x and y directions for each scan. Scan areas 
are highlighted throughout by a black box with a 
broken line. 
Processing of SERS microscopy images 
Cosmic ray removal, background subtraction, 
spectral smoothing (n=5 pixels) and direct classical 
least squares (DCLS) analysis were performed in the 
WiRE 4.3 software. False color images were generated 
from the DCLS results, with the look-up table 
thresholds set to minimize the influence of noise and 
highlight the Raman spectra in the map in greatest 
agreement with reference BFNP spectra. Look-up 
table settings for all Raman images are shown in 
Figure S1. 
SERS spectroscopy 
Raman spectra from coronary arteries and 
animals treated with BFNP were collected using an 
in-house instrument described previously [27]. 
Briefly, the system consists of a attenuable 785 nm 
laser (Innovative Photonics Solutions, Monmouth 
Junction, NJ), a single fiber optic Raman probe with 
internal filtering (Wasatch Photonics, Durham, NC) 
mounted on an xyz stage (ThorLabs, Newton, NJ) and 
a fixed-grating spectrometer with thermoelectric 
cooling (WP 785, Wasatch Photonics). This excitation 
wavelength was selected for spectroscopy due to 
lower tissue absorption and damage when analyzing 
tissues ex/in vivo whilst maintaining signal detection 
efficiency. Typical spectral acquisition settings 
consisted of 1 s acquisitions with 30-40 mW of power 
at the sample, depending on the prominence of 
auto-fluorescence background. Background 
contributions were removed in WiRE 4.3, as in 
microscopy images. 
Quantification of SERS spectra using DCLS 
Direct classical least squares data analysis 
(DCLS) was performed in the Wire 4.3 software. Prior 
to DCLS fitting, cosmic ray removal, background 
subtraction, and spectral smoothing (n=5 pixels) were 
performed on individual spectra from each Raman 
map. All spectra in the map were then averaged, 
creating a single representative spectrum per 2D 
Raman scan. DCLS was performed on these spectra 
using four reference spectra, one from each of the 
three targeted particles and the isotype control, 
resulting in a score for each Raman reporter for each 
averaged spectrum. Each Raman reporter score was 
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averaged from 12 imaged cells per condition, with the 
standard deviation representing the error. 
Quantification of SERS spectra using Bayesian 
modeling 
Bayesian statistical analysis was performed in 
the R statistical computing platform [28]. Prior to 
Bayesian fitting, cosmic ray removal was conducted 
on individual spectra from each Raman map. All 
spectra in each map were then averaged, creating a 
single representative spectrum per 2D Raman scan. 
Bayesian linear regression was then performed using 
four reference spectra and a penalized cubic spline 
modeling the baseline as in Moores et al. [29]. For 
baseline modeling, baseline knots were placed 5 
wavenumbers apart. For the prior distributions of the 
scores, truncated normal distributions with mean 0, 
standard deviation 4000 and truncation at 0 were 
selected as scores must be non-negative. For the 
baseline parameters, we chose a multivariate Normal 
distribution with mean 0, and precision matrix 10-6 (I 
+ λFTF), where I is the identity matrix, λ is the 
roughness penalty, and F is the matrix of second order 
finite difference coefficients. For each representative 
spectrum, λ was chosen by fitting a penalized cubic 
spline to a region with no peaks. Finally, for the 
variance of the errors, we chose an inverse-Gamma 
distribution with shape 0.001 and scale 2500. We 
obtained 1000 sequential Monte Carlo samples from 
the relevant posterior distribution for each spectrum 
[29]. Spectra were then grouped according to 
stimulation condition and 12 posterior sample 
members were averaged within each group to give 
1000 average scores per reference spectra per 
stimulation condition. 
Statistical analysis 
Statistical analyses were performed using 
GraphPad Prism Version 6.0 (GraphPad, CA, USA). 
Statistical significance was calculated using ordinary 
one-way ANOVA with post-hoc Tukey’s test, and R2 
values were calculated using linear regression. 
Statistical significance was defined as P<0.05. We 
used Bayesian linear regression [30] to obtain 
posterior probabilities of differences between means 
from the 1000 average scores. In this case, significance 
was defined as <5% overlap between the scores. 
Results 
Synthesis of SERS-active BFNP for SERS 
molecular imaging 
BFNP were designed and synthesized consisting 
of a surface-enhancing gold core, a Raman reporter to 
endow a unique Raman spectral signature, 
polyethylene glycol (PEG) for stability, 
biocompatibility and prolonged in vivo circulation 
times, and antibodies to provide target molecule 
specificity. A BFNP schematic is shown in Figure 
S2A. The ability to discriminate multiple BFNP with 
different molecular targets was achieved by pairing 
each antibody/NP combination with a unique Raman 
reporter. The spectrum of each Raman reporter 
utilized is shown, with the unique spectral features 
used for their identification highlighted (Figure S2B). 
The primary antibody/reporter combinations selected 
were: isotype-DP (4,4- dipyridyl), identified by a peak 
at 1296 cm-1; anti-ICAM-1-BPE (1,2-bis(4-pyridyl) 
ethylene), identified by a peak at 1202 cm-1 (in a 
multiplex, this shift appears as a deviation or 
“shoulder” on a larger peak at 1215 cm-1); 
anti-VCAM-1-PYOT(5-(pyridine-4-yl)-1,3,4-oxadiazol
e-2-thiol), identified by a peak at 1575 cm-1; 
anti-P-selectin-PPY (4-(1H-pyrazol-4-yl)pyridine), 
identified by a peak at 952 cm-1. A Raman shift 
common to all BFNP was observed at 1605 cm-1 and 
was used to indicate the general presence of BFNP in 
the absence of delineating spectral features. BFNP 
were ~80 nm in diameter, regardless of the specific 
functionalization (Figure S2C), with Zeta potentials 
below -25 mV demonstrating chemical stability [31] 
(Figure S2D). BFNP displayed no evidence of toxicity 
at 20 µg/L, the maximum concentration used on live 
cells in vitro (Figure S3). 
SERS imaging of BFNP facilitates 
simultaneous and quantifiable multiplexed 
detection of adhesion molecules on human 
endothelial cells in vitro 
 SERS-BFNP facilitates adhesion molecule imaging 
in fixed endothelial cells 
An immunohistochemistry (IHC)-like approach 
in tumor necrosis factor (TNF)-α-stimulated human 
coronary artery endothelial cells (CAEC) was used 
initially. Stimulated cells expressed ICAM-1, VCAM-1 
and P-selectin as demonstrated by conventional 
immunofluorescence (Figure 1A). The ability of 
anti-ICAM-1-BPE, anti-VCAM-1-PYOT and 
anti-P-selectin-PPY BFNP to bind to their respective 
targets individually on acetone-fixed endothelial cells 
was investigated (Figure 1B). SERS microscopy 
analysis of TNF-α-stimulated CAEC identified the 
binding of each targeted probe to its specific target in 
isolation, but, as expected, the DP-labeled isotype 
control probes did not bind. We confirmed that the 
choice of reporter molecules did not influence binding 
of BFNP to target molecules by showing that 
anti-ICAM-1 BFNP functionalized with PPY, BPE, 
PYOT and DP produced similar results, whilst isotype 
equivalents produced low-to-no signal (Figure S4). 
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The simultaneous detection and discrimination of 
ICAM-1, VCAM-1 and P-selectin was demonstrated 
by exposing activated CAEC to an equimolar mixture 
of anti-ICAM-1-BPE, anti-VCAM-1-PYOT, 
anti-P-selectin-PPY and isotype-DP probes, with 
isotype probes producing low-to-no signal in all 
experiments (Figure 1C). Darkfield images indicated 
the presence of BFNP on cells, appearing as small 
bright spots due to their unique scattering properties, 
whilst delineation of particle type was achievable via 
the Raman spectra collected. Examples of individual 
spectra acquired from within the Raman maps are 
shown, confirming that the experimentally observed 
spectra from specific points in the Raman map match 
prototypical reference spectra for each of the three 
targeted probes (Figure 1D). These results 
demonstrate the multiplexed detection of three 
adhesion molecules using our SERS-BFNP approach 
in fixed endothelial cells. 
 
 
Figure 1. Following stimulation, coronary artery endothelial cells (CAEC) express adhesion molecules detectable via immuno-SERS imaging in 
single and multiplex formats. (A) Fluorescence images of immunohistochemical staining of ICAM-1, VCAM-1 and P-selectin on CAEC in unstimulated and 10 
ng/mL TNF-α-stimulated conditions. Isotype control, ICAM-1, VCAM-1 and P-selectin staining shown in green; nuclei were counterstained using Hoechst 33342 
(blue). (B) CAEC were stimulated with 10 ng/mL TNF-α for 24 h, fixed in acetone, and incubated with isotype control, anti-ICAM-1, anti-VCAM-1 or anti-P-selectin 
BFNP or (C) with all BFNP simultaneously before being subjected to SERS mapping. (D) Representative spectra from anti-ICAM-1 (purple), anti-VCAM-1 (red) and 
anti-P-selectin (blue) BFNP acquired from the color-matched circles in (C) are shown above their respective reference spectra. Optical images in (B-C) are darkfield 
images. Scale bars = 20 μm. Results are representative of 3 independent experiments. 
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SERS-BFNP approach facilitates adhesion molecule 
imaging in live endothelial cells 
SERS-BFNP imaging in live endothelial cells was 
shown to be successful by exposing TNF-α-stimulated 
CAEC to a mixture of anti-ICAM-1-BPE, 
anti-VCAM-1-PYOT, anti-P-selectin-PPY and 
isotype-DP probes (Figure S5A). Using Raman and 
darkfield imaging, an increase in the amount of 
anti-ICAM-1 BFNP was observed when incubation 
with the probe mixture was increased from 30 min to 
3 h; this was not observed with anti-VCAM-1 or 
anti-P-selectin probes. We hypothesize that the 
increase in anti-ICAM-1 probe signal may be as a 
result of BFNP uptake by CAECs. Transmission 
electron microscopy (TEM) analysis of 
TNF-α-stimulated CAECs exposed to single varieties 
of BFNP, to facilitate differentiation of particles in the 
absence of correlated spectral information afforded by 
SERS, identified an abundance of anti-ICAM-1 NPs 
located within cytoplasmic vesicles after 24 h. 
Anti-VCAM-1, anti-P-selectin and isotype BFNP were 
detected infrequently or not at all (Figure S5B). These 
data confirm the ability of BFNP to bind to their 
molecular targets and be detected using SERS 
microscopy in live cells, whilst highlighting that 
ICAM-1 targeted probes can be internalized by 
CAECs. 
Adhesion molecule expression is semi-quantifiable 
using SERS-BFNP approach 
Information obtained from Raman imaging of 
the BFNP on fixed cells was used to develop a 
semi-quantitative approach to monitor changes in 
biomarker expressions. Human umbilical vein 
endothelial cells (HUVEC) were employed, which 
demonstrated a lower basal but similar induced 
expression of adhesion molecules in comparison with 
CAECs (data not shown). Conventional 
immunofluorescence microscopy (IFM) analysis of 
HUVEC identified a concentration-dependent 
response to TNF-α in respect to adhesion molecule 
expression (Figure 2A). In parallel, stimulation of 
HUVEC with increasing TNFα concentrations 
increased binding of anti-ICAM-1-BPE, 
anti-VCAM-1-PYOT and anti-P-selectin-PPY, but not 
isotype-DP BFNP, as measured by multiplexed SERS 
microscopy (Figure 2B). In order to quantify these 
results, the cumulative spectra of each Raman/SERS 
map were averaged to establish one representative 
spectrum per SERS microscopy image. The increasing 
adhesion molecule SERS signal observed by 
Raman/SERS mapping was conserved in these 
spectra (Figure 2C), with the spectral intensity at 
Raman shifts related to each of the BFNP increasing 
with TNF-α concentration. 
Quantification of immunofluorescence images 
confirmed the concentration-response relationship 
between TNF-α stimulation and HUVEC expression 
of ICAM-1, VCAM-1 and P-selectin (Figure 2D). This 
single marker immunofluorescence quantification 
was as a standard with which to compare two 
multiplexed SERS quantification methodologies: one 
using direct classical least squares (DCLS) and the 
other using a Bayesian approach. Two quantification 
methods were explored as a standard method of 
quantification that is rigorous and robust enough for 
broad application; a unanimous model has yet to be 
defined due to the novelty of SERS quantification 
methodologies. Crucially, the quantification scores for 
both DCLS (Figure S6A) and Bayesian (Figure S6B) 
approaches increased linearly with BFNP 
concentration, indicating their suitability as a means 
of quantifying SERS signals. Both quantification 
methodologies produced near-zero scores in all 
stimulation conditions explored for isotype control 
BFNP (Figure S7). DCLS analysis of stimulated 
HUVEC with multiplexed BFNP produced a similar 
concentration-response relationship as observed with 
single marker IFM, with different stimulation 
conditions resulting in observation of significant 
differences for each adhesion molecule (Figure 2D). 
Additionally, by using a Bayesian approach, which 
quantifies each spectrum 1000 times, a TNF-α 
concentration response was found that was similar to 
that observed with IFM, further corroborating the 
DCLS analysis (Figure 2D). IFM analysis correlated 
highly with both DCLS and Bayesian SERS 
quantification methodologies (Figure 2E). In 
summary, SERS imaging of BFNP can be used for the 
quantifiable multiplex detection of adhesion 
molecules on human endothelial cells in vitro. 
SERS imaging of BFNP facilitates 
simultaneous multiplex detection of adhesion 
molecules in human coronary artery ex vivo 
The SERS detection approach was applied in 
human tissue ex vivo using a single Raman fiber 
probe-configured, custom-made spectroscopic system 
[27]. Fresh segments of human coronary arteries from 
patients undergoing heart transplantation were 
obtained for this study. Clinical characteristics and 
summary SERS-BFNP results for all vessels are shown 
in Table S1. Vessels which did not present any 
evidence of atherosclerosis did not lead to the 
detection of significant adhesion molecules using any 
spectroscopic approach (Figure S8). The artery shown 
in Figure 3 contained an atherosclerotic plaque, with 
tissue remodeling and lipid accumulation evident 
(Figure 3A), that also had an intact endothelium 
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(Figure 3B). ICAM-1 and P-selectin were present on 
both atherosclerotic and non-atherosclerotic regions 
of tissue, whilst VCAM-1 was only identified on 
atherosclerotic tissue (Figure 3C). 
 
 
Figure 2. Quantification of adhesion molecule expression by SERS-BFNP molecular imaging using DCLS and Bayesian methodologies. (A) 
Immunofluorescence staining of ICAM-1, VCAM-1 and P-selectin on human umbilical vein endothelial cells cultured for 6 h in unstimulated, 0.001, 0.1 or 10 ng/mL 
TNF-α-stimulated conditions. Adhesion molecule staining is shown in white; all cells were counterstained with Hoechst 33342 to identify nuclei (blue). (B) HUVEC 
were cultured unstimulated or stimulated with 0.001, 0.1 or 10 ng/mL TNF-α for 6 h, fixed in acetone, and incubated with anti-ICAM-1, anti-VCAM-1, anti-P-selectin, 
and isotype control BFNP simultaneously. Cells were then subjected to SERS mapping. Each channel from representative multiplex images are shown for: anti-ICAM-1 
(purple), anti-VCAM-1 (red), anti-P-selectin (blue), isotype (green) BFNP. (C) For quantification, spectra from each SERS microscopy image were averaged to provide 
one spectrum per image; a representative spectrum for each TNF-α condition is shown. (D) Integrated densities alongside DCLS and Bayesian SERS quantification 
scores were calculated for ICAM-1, VCAM-1 and P-selectin expression from each TNF-α-stimulated condition. (E) The correlation between immunofluorescence 
integrated density and DCLS/Bayesian quantification methodologies and their respective R2 values are shown. Optical images in (B) are darkfield images. Scale bars = 
20 μm. Each Raman reporter score was averaged from 12 imaged cells per condition. Values are mean ± SD. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. In the 
Bayesian quantification, we indicate where the posterior probability of the difference between the group means being greater than zero is >95% (*), >99% (**), >99.9% 
(***). 
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Figure 3. SERS-BFNP molecular imaging of atherosclerotic coronary arteries. A single human coronary artery was isolated from the heart of a patient 
undergoing heart transplantation surgery. The lumen of the artery segment was then injected with a mixture of anti-ICAM-1, anti-VCAM-1, anti-P-selectin, and 
isotype control BFNP, sutured closed, and incubated at 37 °C/5% CO2 for 12 h. Sutures were then removed and the artery segment was thoroughly washed prior to 
SERS spectroscopy and subsequent analysis of morphology, expression of adhesion molecules and SERS mapping. (A) Photos are shown of an intact (upper left panel) 
and dissected en face opened (upper middle panel) atherosclerotic artery. The plaque location is highlighted with a red circle. Following SERS spectroscopy analysis, 
the opened artery was bisected to separate atherosclerotic and non-atherosclerotic regions of the vessel; the cut location is highlighted with a black dashed line 
(upper right panel). H&E (lower left panel) and Oil Red O staining (lower right panel) were carried out to investigate vessel morphology and lipid deposits, 
respectively. (B) Immunofluorescence staining for CD31, and expression of (C) ICAM-1, VCAM-1 and P-selectin are shown in red. Nuclei were counterstained using 
Hoechst 33342 (blue). (D-E) SERS spectroscopy was conducted on atherosclerotic (red lines) and non-atherosclerotic (black lines) regions of the intact (D) and 
opened (E) artery. The unique peaks and common peak used to identify each BFNP configuration are highlighted with a red arrow and dotted line, and labeled 
accordingly. Spectroscopy results are displayed as spectra averaged from at least 3 different points within the atherosclerotic and non-atherosclerotic regions. (F) 
ICAM-1, VCAM-1, P-selectin, and isotype signals were quantified using DCLS, with each point representing a spectrum acquired from a different location with either 
atherosclerotic or non-atherosclerotic regions of the opened vessel. (G-H) SERS mapping was then carried out for anti-ICAM-1 (purple), anti-VCAM-1 (red), 
anti-P-selectin (blue), and isotype (green) BFNP. Darkfield images are shown and the regions of non-atherosclerotic (G) and atherosclerotic (H) artery subject to 
SERS mapping are highlighted with yellow and red boxes corresponding to SERS maps on the right of each darkfield image. Optical images in (G-H) are darkfield 
images. Scale bars: (A-B) = 500 µm; (C) = 100 µm; (G-H) = 500 μm (black bar) and 20 μm (white bar). 
 
Exposure of the artery to an equimolar mixture 
of anti-ICAM-1-BPE, anti-VCAM-1-PYOT, anti-P- 
selectin-PPY and isotype-DP BFNP facilitated SERS 
spectroscopic detection of ICAM-1, VCAM-1 and 
P-selectin on the plaque, with higher ICAM-1 and 
P-selectin intensity than in non-atherosclerotic 
regions, and VCAM-1 found only on the 
atherosclerotic region (Figure 3D). To confirm the 
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accuracy of these results, the artery was opened and 
the Raman spectroscopic investigation was repeated, 
allowing more rigorous control of the location being 
analyzed and improved sampling (Figure 3E). This 
analysis confirmed the detection of ICAM-1, VCAM-1 
and P-selectin on atherosclerotic tissue. Using the 
DCLS quantification strategy, the results obtained 
from this artery were quantified, producing a 
numerical trend towards increased adhesion molecule 
expression, but no change in isotype signal, when 
comparing atherosclerotic to non-atherosclerotic 
regions of tissue (Figure 3F). 
Both the atherosclerotic and non-atherosclerotic 
regions of tissue were subsequently examined by 
SERS microscopy, which confirmed the high 
positivity of ICAM-1, VCAM-1 and P-selectin on 
atherosclerotic endothelium, and only infrequent 
detection of ICAM-1 and VCAM-1 on 
non-atherosclerotic tissue (Figure 3G-H). 
Furthermore, BFNP-related darkfield contrast at the 
endothelial surface of atherosclerotic tissue was 
visibly increased compared with that at 
non-atherosclerotic regions, suggesting far greater 
BFNP density at this tissue site. In summary, these 
data confirm the suitability of this SERS-BFNP 
platform for simultaneous multiplexed detection of 
adhesion molecules in human atherosclerotic artery ex 
vivo. 
SERS imaging of BFNP facilitates 
simultaneous multiplex detection of adhesion 
molecules in vivo 
The ultimate test is whether the SERS-BFNP 
approach could be applied for molecular imaging of 
adhesion molecules in vivo. To achieve this, a 
humanized mouse model (HANSG model) was used 
whereby NSG mice, which are amenable to 
xenografting due to their immunocompromised 
status [32,33], were engrafted with human 
subcutaneous adipose tissue. Adipose engraftment 
resulted in NSG mice containing viable and perfused 
human microvasculature (Figure S9). The presence of 
human vessels, which were identified microscopically 
in close proximity to the murine vasculature, was 
confirmed (Figure 4A). Furthermore, it was found 
that following an intravenous injection of TNF-α, 
these vessels expressed ICAM-1 and P-selectin; in 
contrast, there was no evidence of VCAM-1 (Figure 
4B). To test SERS-BFNP molecular imaging in vivo, 
HANSG mice were intravenously injected with TNF-α, 
and 4 h later [34] received BFNP functionalized with 
anti-ICAM-1-BPE, anti-VCAM-1-PYOT and 
anti-P-selectin-PPY; control mice received 
isotype-BPE, isotype-PYOT and isotype-PPY. These 
mice were then subjected to non-invasive in vivo SERS 
spectroscopy, as demonstrated in Figure 4C. At 24 h 
post injection, there was little to no signal from BFNP 
in the blood, suggesting clearance from the 
circulation, with BFNP signal from the liver being 
similar for both isotype and targeted probes at 1 h and 
24 h post-BFNP injection (Figure S10). 
SERS spectra at 24 h following BFNP injection in 
mice that received a mixture of targeted BFNP 
demonstrated ICAM-1 and P-selectin single detection, 
as well as their simultaneous duplex detection. The 
peak common to all reporter molecules is present in 
all spectra from the targeted mice; in contrast, BFNP 
signals were not observed in mice receiving 
equivalent isotype controls. Spectra obtained from 5 
isotype and 5 targeted mice are shown (Figure 4D). 
Subsequent SERS microscopy analysis identified the 
presence of ICAM-1, VCAM-1 and P-selectin in mice 
that received targeted BFNP, but showed no evidence 
of isotype probes in the control group (Figure 4E). 
Examples of individual SERS spectra acquired within 
microscopy images are shown, confirming that the 
experimentally observed spectra from specific points 
in the Raman image match prototypical reference 
spectra for each of the three targeted probes (Figure 
4F). In summary, these data demonstrate the 
successful application of a SERS-BFNP imaging 
approach in vivo for multiplexed non-invasive 
imaging of adhesion molecules. 
Discussion 
In this study, we have demonstrated the 
feasibility of a SERS-BFNP molecular imaging 
platform for non-invasive, simultaneous targeted 
multiplexed detection of adhesion molecules in vivo in 
the context of vascular inflammation. There is great 
interest in the ability to image specific inflammatory 
biomarkers from the clinical perspective, as 
inflammation plays fundamental roles in 
atherosclerosis, but at present there are significant 
limitations in the potential to observe these molecules 
in patients. As such, this study will have important 
implications for potentiating the development of 
clinical SERS-BFNP molecular imaging systems in the 
cardiovascular setting and in any other pathology in 
need of multiplexed biomarker imaging. 
Molecule-specific BFNP were developed—a 
strategy employed in several other studies 
[16,17,19-22,35]—as a means of detecting adhesion 
molecules using SERS. We have targeted adhesion 
molecules as a proof of concept, given that they are 
easily accessible to intravenously injected contrast 
agents. The capability of the BFNPs to bind 
specifically to their molecular targets, facilitating 
simultaneous imaging of ICAM-1, VCAM-1 and 
P-selectin, has been convincingly demonstrated using 
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SERS microscopy. Supporting previous studies using 
BFNP as drug delivery systems [36,37], it was found 
that ICAM-1-targeted particles were internalized by 
CAECs, resulting in amplification of the SERS signal 
and presenting a mechanism that could be 
manipulated for theranostic drug delivery or 
improving imaging depth. 
 
 
Figure 4. In vivo SERS-BFNP molecular imaging of adhesion molecules. Following engraftment of human adipose, HANSG mice were allowed to recover for 
3 weeks. Mice were then injected intravenously with 5 μg of human recombinant TNF-α 4 h prior to receiving an intravenous injection of BFNP. (A) Following 
SERS-BFNP molecular imaging, adipose grafts were excised and immunofluorescently stained for human (red) and murine (green) CD31. (B) Isotype control, 
ICAM-1, VCAM-1, and P-selectin staining are also shown in white counterstained with human CD31 (red). Nuclei were counterstained using Hoechst 33342 (blue). 
(C) To conduct SERS-BFNP molecular imaging, HANSG mice were anaesthetized and their adipose grafts non-invasively analyzed in vivo using SERS spectroscopy. (D) 
SERS spectra were acquired from mice that received a mixture of isotype-PPY, -BPE and -PYOT (blue spectra), or anti-P-selectin-PPY, anti-ICAM-1-BPE, 
anti-VCAM-1-PYOT BFNP (red spectra). The spectra shown are from 5 isotype vs. 5 targeted mice, with each spectrum acquired from a different mouse. (E) In 
addition to immunofluorescence microscopy, excised adipose grafts were analyzed using SERS microscopy. Detection of BFNP from sections of adipose tissue 
isolated from HANSG mice that received anti-ICAM-1 (purple), anti-VCAM-1 (red), and anti-P-selectin (blue) (upper panels) or Isotype-BPE (purple), Isotype-PYOT 
(red), and Isotype-PPY (blue) (lower panels) are shown superimposed on darkfield tissue images alongside a magnified image of Raman maps from the scanned areas 
(black boxes). The colored circles in the Raman map ((E) upper panel) correlate to the acquired spectra shown in (F) above their respective reference spectra. The 
optical image in (E) is a darkfield image. Scale bars: (A) = 1000 μm; (B) = 100 μm; (E) = 20 μm. 
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Quantification of adhesion molecule expression 
using the SERS-BFNP molecular imaging system was 
achieved and, in the process, demonstrated that both 
DCLS and Bayesian multiplexed quantification 
approaches correlated well with a classical 
immunofluorescence methodology in vitro. Building 
on the work of the Liu group [38-43], who have 
developed a semi-quantitative SERS-BFNP approach 
for tumor phenotyping, an isotype BFNP was 
included in the multiplex probe panel as an internal 
standard for non-specific binding. Due to variable 
levels of non-specific binding observed in different 
tumor types, the phenotyping of tumors in the 
referenced studies required ratiometric normalization 
of biomarker scores to isotype BFNP scores. In 
comparison, normalization was not required in this 
study due to near zero scores for isotype-BFNP in all 
conditions analyzed. The ability to quantify vascular 
inflammatory biomarkers would be most 
advantageous, as it is the balance between pro- and 
anti-inflammatory mechanisms that will define 
pathological outcomes [2,44,45]. 
Raman spectroscopy imaging approaches, which 
focus on detecting the native spectral fingerprints of 
tissue components such as calcium and collagen, have 
demonstrated the ability to differentiate 
atherosclerotic and non-atherosclerotic arteries with 
reasonable success [46-48]. However, acquisition of 
Raman signals from atherosclerotic plaques in vivo 
requires the use of invasive intravascular probes due 
to the inherent lack of tissue penetration commonly 
associated with Raman spectroscopy. By comparison, 
the use of targeted BFNP in a SERS approach greatly 
expands the number of biomarkers one could image, 
whilst providing the sensitivity needed to detect 
spectra through several centimeters of tissue, thus 
offering the potential for non-invasive use in 
superficial arteries [27,49,50]. To put the multiplexing 
potential into context, identification and 
discrimination of 10 non-targeted SERS nanoprobes 
has been demonstrated in vivo, making expansion of 
the number of target molecules simultaneously 
imaged a distinct possibility in the future [51]. 
The SERS-BFNP molecular imaging approach 
used here successfully detected adhesion molecules in 
fresh human coronary artery. Specifically, SERS 
spectroscopic detection of adhesion molecules was 
only achieved in atherosclerotic arteries, highlighting 
the potential for discriminating atherosclerotic from 
non-atherosclerotic tissue. The incorporation of 
additional biomarkers related to inflammation, 
angiogenesis or thrombotic pathways would allow 
increased sensitivity of detection and potentially 
plaque phenotyping in respect to detecting early stage 
lesions and atherosclerosis at high risk of causing a 
clinically significant event. Furthermore, the DCLS 
quantification approach tested in vitro verified our 
interpretations of plaque vs. non-plaque spectra in a 
human coronary artery, with increased ICAM-1, 
VCAM-1 and P-selectin signal in the atherosclerotic 
tissue regions. Though there are a low number of 
replicates due to the limited availability of these 
valuable tissues, these results demonstrate 
SERS-BFNP multiplex molecular imaging of adhesion 
molecules in human coronary arteries, whilst the data 
also suggests that DCLS quantification may be 
applicable to spectra obtained from tissues. 
The limited number of studies exploring 
multiplex-capable SERS-BFNP approaches in vivo—all 
of which are in the cancer field—utilized adoptive 
transfer of hundreds of thousands to millions of 
tumor cells into immunocompromised mice, leading 
to the generation of large palpable tumors [19,21]. In 
comparison, the HANSG mice in this study possessed 
at least an order of magnitude fewer endothelial cells, 
the primary expressers of adhesion molecules in the 
transplanted adipose tissue. Despite the small 
population of endothelial cells, simultaneous 
detection of human ICAM-1 and P-selectin in HANSG 
mice in vivo using SERS was achieved. Confidence in 
the accuracy of this result was obtained by subsequent 
ex vivo immunofluorescence staining confirming the 
expression of these adhesion molecules and the 
absence of VCAM-1. 
Like all nanoparticle-based approaches, there are 
many challenges ahead in respect to translating 
research-grade nanoparticle formulations to those 
suitable for use in humans [52]. To achieve this goal, 
BFNPs must be: synthesized under sterile conditions 
in GLP facilities to clinical-grade quality, preferably 
using substances with historical use in humans, such 
as gold and PEG; assessed for potential 
immunogenicity; studied in respect to biodistribution, 
toxicology and pharmacokinetics; standardized to 
ensure minimal batch-to-batch variation; and 
rigorously tested for long term potency and stability. 
However, with research in this area expanding 
alongside use of antibodies as therapeutics and 
targeting agents, it is likely that these challenges will 
be overcome in the near future. 
Conclusions 
The demonstrations that SERS-BFNP approaches 
are fruitful in vivo, in combination with the numerous 
technical advances currently being made, supports 
SERS as a technology worthy of intense investigation 
for both invasive and non-invasive molecular imaging 
of vascular inflammation and atherosclerosis. This 
study not only opens new avenues for unprecedented 
multiplexed molecular imaging of vascular 
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inflammation in experimental models, but also 
highlights the possibility to develop SERS further for 
clinical use. SERS is one of the few current 
technologies offering true multiplexing capability for 
molecular imaging of vascular inflammation, and the 
development of SERS-based approaches in 
conjunction with conventional anatomical imaging 
modalities may facilitate early diagnosis of vulnerable 
plaques and patient stratification for treatment with 
anti-inflammatory therapies. The theoretical potential 
for simultaneous in situ imaging of tens of 
inflammatory biomarkers would also facilitate 
investigation of new therapeutic avenues by allowing 
real-time monitoring of inflammatory pathways in 
patients and advancing the management of many 
pathologies including cancer, autoimmunity and 
infectious diseases. 
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